SSRIs produce statistically significant but modest improvements over placebo in depression, with benefit concentrated in severe cases and diminished in mild-to-moderate cases.
Pooled analyses show SSRIs yield modest benefits over placebo for major depressive disorder, with clinically meaningful effects primarily in patients with severe depression. In mild-to-moderate cases, the advantage over placebo is diminished. The paper suggests SSRIs act by reducing negative affective bias and enhancing neuroplasticity rather than correcting a serotonin deficit.
Evidence Score
Study Evidence
Study 1. Rethinking Serotonin in Depression: Toward a Modern Clinical Framework.
observationalSheppert A · Cureus (2026)
Result:
Mechanism Graph
Limitations
- ⚠Effect size is modest and not clinically meaningful for all patients
- ⚠Benefit is diminished in mild-to-moderate depression, limiting generalizability
- ⚠Pooled analyses include multiple antidepressant classes, not just SSRIs
Frequently Asked Questions
Do SSRIs work for mild depression?▼
The evidence suggests benefit is diminished in mild-to-moderate cases, with modest improvements over placebo.
What is the proposed mechanism of SSRIs if not correcting serotonin deficiency?▼
SSRIs are thought to reduce negative affective bias and enhance neuroplasticity, creating a window for psychosocial interventions.
Are SSRIs still recommended as first-line treatment?▼
Recent guidelines from WHO, NICE, and APA prioritize psychological therapies, exercise, and combination approaches over antidepressant monotherapy for non-severe depression.
What are common side effects of SSRIs mentioned?▼
Common adverse effects include sexual dysfunction, weight gain, and sleep disturbance.
Products
Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.
References
- 1.Sheppert A. "Rethinking Serotonin in Depression: Toward a Modern Clinical Framework.." Cureus, 2026. PMID: 42473512 DOI: 10.7759/cureus.111172